 |
89 Diseases |  |
30 Trials |
|
30 Trials |  |
3067 News |  |
| «12...17181920212223242526272829» |
- ||| Lantus (insulin glargine) / Sanofi, Apidra (insulin glulisine) / Sanofi
Enrollment closed, Surgery: RABBIT 2-SX: Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery (clinicaltrials.gov) - Oct 3, 2012
P4, N=234, Active, not recruiting, Sponsor: Emory University
Completed --> Active, not recruiting
- Januvia (sitagliptin) / Merck (MSD)
Trial completion: Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes (clinicaltrials.gov) - Oct 3, 2012
P4, N=90, Completed, Sponsor: Emory University
Completed --> Active, not recruiting Not yet recruiting --> Completed
- |||| Trial completion: Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM) (clinicaltrials.gov) - Oct 3, 2012
P4, N=375, Completed, Sponsor: Guillermo Umpierrez
Not yet recruiting --> Completed Recruiting --> Completed
- ||| Lantus (insulin glargine) / Sanofi
Trial completion: Effectiveness of Adding Subcutaneous Long-acting Glargine to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy (clinicaltrials.gov) - Oct 1, 2012
P=N/A, N=60, Completed, Sponsor: University of Colorado, Denver
Recruiting --> Completed Recruiting --> Completed
- | Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
Trial completion: A Study of LY2963016 in Healthy Participants (clinicaltrials.gov) - Sep 27, 2012
P1, N=28, Completed, Sponsor: Eli Lilly and Company
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
Trial completion: ELEMENT 2: A Study in Adults With Type 2 Diabetes (clinicaltrials.gov) - Sep 27, 2012
P3, N=606, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Lantus (insulin glargine) / Sanofi
Trial completion: Insulin Secretion in Diabetes Before and After Glycemic Control (clinicaltrials.gov) - Sep 20, 2012
P=N/A, N=17, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Recruiting --> Completed
- |||||||||| Lantus (insulin glargine) / Sanofi
New P3 trial, Combination therapy: EDITION JP II: Comparison of a New Formulation of Insulin Glargine With Lantus (clinicaltrials.gov) - Sep 19, 2012
P3, N=240, Active, not recruiting, Sponsor: Sanofi
- |||||||||| Lantus (insulin glargine) / Sanofi
New P3 trial: EDITION JP I: Comparison of a New Formulation of Insulin Glargine With Lantus (clinicaltrials.gov) - Sep 19, 2012
P3, N=240, Active, not recruiting, Sponsor: Sanofi
- ||| Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
New P1 trial: A Study to Compare LY2963016 and US-approved Lantus (clinicaltrials.gov) - Sep 18, 2012
P1, N=78, Completed, Sponsor: Eli Lilly and Company
- Humalog pen (insulin lispro) / Eli Lilly, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Enrollment change: HMH: Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin (clinicaltrials.gov) - Sep 11, 2012
P3, N=16, Terminated, Sponsor: Eli Lilly and Company
Recruiting --> Completed N=266 --> 16
- |||||||||| Lantus (insulin glargine) / Sanofi
New P3 trial: EDITION IV: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Sep 9, 2012
P3, N=551, Completed, Sponsor: Sanofi
- |||||||||| Lantus (insulin glargine) / Sanofi
New P3 trial: EDITION III: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy (clinicaltrials.gov) - Aug 28, 2012
P3, N=881, Completed, Sponsor: Sanofi
- | Lantus (insulin glargine) / Sanofi
New P1 trial: Repeated Dose Study With a New Insulin Glargine Formulation and Lantus (clinicaltrials.gov) - Aug 28, 2012
P1, N=20, Completed, Sponsor: Sanofi
- |||| Apidra (insulin glulisine) / Sanofi
Trial completion: CHANGING: Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs (clinicaltrials.gov) - Aug 28, 2012
P4, N=207, Completed, Sponsor: Sanofi
N=266 --> 16 Active, not recruiting --> Completed
- |||| Lantus (insulin glargine) / Sanofi, Apidra (insulin glulisine) / Sanofi
Trial completion: B to B: Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM) (clinicaltrials.gov) - Aug 19, 2012
P4, N=161, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Lantus (insulin glargine) / Sanofi
Head-to-Head: LANCELOT: Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment (clinicaltrials.gov) - Aug 19, 2012
P4, N=708, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Lantus (insulin glargine) / Sanofi
New P2 trial: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin (clinicaltrials.gov) - Aug 5, 2012
P2, N=60, Completed, Sponsor: Sanofi
- | Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
Trial completion: A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Jul 29, 2012
P1, N=20, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
Trial completion: A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants (clinicaltrials.gov) - Jul 29, 2012
P1, N=98, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | New P4 trial, Post-transplantation: PTHG: Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia (clinicaltrials.gov) - Jul 22, 2012
P4, N=120, Recruiting, Sponsor: Vancouver General Hospital
- Enrollment change: Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168) (clinicaltrials.gov) - Jul 4, 2012
P1, N=36, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed N=24 --> 36
- | Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
New P1 trial: A Study of LY2963016 in Healthy Participants (clinicaltrials.gov) - Jul 4, 2012
P1, N=28, Completed, Sponsor: Eli Lilly and Company
- | Trial completion: Pharmacodynamic and Pharmacokinetic Variability of a Basal Insulin (0000-168) (clinicaltrials.gov) - Jun 5, 2012
P1, N=36, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=24 --> 36 Active, not recruiting --> Completed
- | Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
New P1 trial: A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - May 15, 2012
P1, N=20, Completed, Sponsor: Eli Lilly and Company
- |||||||||| Lantus (insulin glargine) / Sanofi, Adlyxin (lixisenatide) / Sanofi
New P2/3 trial: Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin (clinicaltrials.gov) - May 9, 2012
P2/3, N=142, Completed, Sponsor: Sanofi
- |||| Lantus (insulin glargine) / Sanofi
Trial completion: Pen Preference: Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - May 9, 2012
P4, N=405, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Lantus (insulin glargine) / Sanofi
Trial completion: Single Dose Study With a New Insulin Glargine Formulation and Lantus (clinicaltrials.gov) - Apr 29, 2012
P1, N=18, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Lantus (insulin glargine) / Sanofi
Trial completion: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) (clinicaltrials.gov) - Apr 29, 2012
P3, N=12537, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Lantus (insulin glargine) / Sanofi, Apidra (insulin glulisine) / Sanofi
Trial termination: Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition (clinicaltrials.gov) - Mar 25, 2012
P4, N=15, Terminated, Sponsor: Sanofi
Active, not recruiting --> Completed Completed --> Terminated; Recruitment challenges
- ||| Lantus (insulin glargine) / Sanofi, Apidra (insulin glulisine) / Sanofi
Enrollment change: Self Titration With Apidra to Reach Target Study (START) (clinicaltrials.gov) - Mar 19, 2012
P4, N=493, Completed, Sponsor: Sanofi
Completed --> Terminated; Recruitment challenges N=640 --> 493
- |||| Lantus (insulin glargine) / Sanofi, Apidra (insulin glulisine) / Sanofi
Trial completion: Self Titration With Apidra to Reach Target Study (START) (clinicaltrials.gov) - Mar 19, 2012
P4, N=493, Completed, Sponsor: Sanofi
N=640 --> 493 Recruiting --> Completed
- || Lantus (insulin glargine) / Sanofi
Enrollment change: Lapas II: Basal Insulin for Type 2 Diabetes Patients Treated in Outpatient Clalit Clinics (clinicaltrials.gov) - Mar 6, 2012
P=N/A, N=1229, Completed, Sponsor: Sanofi
Recruiting --> Completed N=450 --> 1229
- ||| Lantus (insulin glargine) / Sanofi
Trial completion: Lapas II: Basal Insulin for Type 2 Diabetes Patients Treated in Outpatient Clalit Clinics (clinicaltrials.gov) - Mar 6, 2012
P=N/A, N=1229, Completed, Sponsor: Sanofi
N=450 --> 1229 Active, not recruiting --> Completed
- |||| Lantus (insulin glargine) / Sanofi, Apidra (insulin glulisine) / Sanofi
Trial completion: GALAPAGOS: Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study (clinicaltrials.gov) - Mar 1, 2012
P4, N=934, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Lantus (insulin glargine) / Sanofi
New P3 trial, Combination therapy: EDITION II: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy (clinicaltrials.gov) - Dec 22, 2011
P3, N=811, Completed, Sponsor: Sanofi
- |||||||||| Lantus (insulin glargine) / Sanofi
New P3 trial: EDITION I: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin (clinicaltrials.gov) - Dec 22, 2011
P3, N=807, Completed, Sponsor: Sanofi
- ||||| Lantus (insulin glargine) / Sanofi
Biomarker, New P4 trial: Establishing Cardiovascular Biomarkers to Define Preferred Lantus (clinicaltrials.gov) - Dec 4, 2011
P4, N=60, Recruiting, Sponsor: ikfe-CRO GmbH
- | Lantus (insulin glargine) / Sanofi
New P1 trial: Single Dose Study With a New Insulin Glargine Formulation and Lantus (clinicaltrials.gov) - Nov 28, 2011
P1, N=18, Completed, Sponsor: Sanofi
- ||||| Lantus (insulin glargine) / Sanofi
New P4 trial: SIMPLE: Simplified Insulin Protocol Using Lantus in Elderly (clinicaltrials.gov) - Nov 27, 2011
P4, N=65, Recruiting, Sponsor: Joslin Diabetes Center
- ||||| Soliqua 100/33 (lixisenatide/insulin glargine) / Sanofi, Lantus (insulin glargine) / Sanofi
New P2 trial: Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients (clinicaltrials.gov) - Nov 20, 2011
P2, N=323, Completed, Sponsor: Sanofi
- ||| Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
New P1 trial: A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants (clinicaltrials.gov) - Nov 20, 2011
P1, N=98, Completed, Sponsor: Eli Lilly and Company
- Humalog pen (insulin lispro) / Eli Lilly, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Trial termination: HMH: Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin (clinicaltrials.gov) - Nov 17, 2011
P3, N=16, Terminated, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Terminated; Low enrollment
- | Lantus (insulin glargine) / Sanofi, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Enrollment open: Comparing Long-acting Insulins During Exercise in Type 1 Diabetes (clinicaltrials.gov) - Nov 6, 2011
P4, N=30, Recruiting, Sponsor: Buckinghamshire Healthcare NHS Trust
Recruiting --> Terminated; Low enrollment Not yet recruiting --> Recruiting
- ||||| Lantus (insulin glargine) / Sanofi
New P4 trial: Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure (clinicaltrials.gov) - Oct 26, 2011
P4, N=89, Completed, Sponsor: Sanofi
- Lantus (insulin glargine) / Sanofi, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion: Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes (clinicaltrials.gov) - Oct 3, 2011
P=N/A, N=10, Completed, Sponsor: University of New Mexico
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| Lantus (insulin glargine) / Sanofi
Enrollment change, Combination therapy: Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial (clinicaltrials.gov) - Sep 19, 2011
P3, N=112, Completed, Sponsor: Sanofi
Recruiting --> Completed N=530 --> 112
- | Lantus (insulin glargine) / Sanofi, Levemir (insulin detemir rDNA origin) / Novo Nordisk
New P4 trial: Comparing Long-acting Insulins During Exercise in Type 1 Diabetes (clinicaltrials.gov) - Sep 19, 2011
P4, N=30, Recruiting, Sponsor: Buckinghamshire Healthcare NHS Trust
- ||||||| Lantus (insulin glargine) / Sanofi
Trial completion, Combination therapy: Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial (clinicaltrials.gov) - Sep 19, 2011
P3, N=112, Completed, Sponsor: Sanofi
N=530 --> 112 Recruiting --> Completed
- |||| Lantus (insulin glargine) / Sanofi
Trial completion, Surgery: Perioperative Insulin Glargine Dosing Study (clinicaltrials.gov) - Aug 21, 2011
P4, N=402, Completed, Sponsor: Tamra Dukatz
Recruiting --> Completed Active, not recruiting --> Completed